TickerTalks
Browse all tickers →
TickerTalks›$SLS
SLSLS

SELLAS Life Sciences Group, Inc.

$SLS·$2.4B·Biotechnology·Healthcare
$13.38+13.8%YTD+164.0%1Y+512.0%
Mentions · last 7 days
2026-07-09: 373 posts2026-07-10: 238 posts2026-07-11: 57 posts2026-07-12: 207 posts2026-07-13: 329 posts2026-07-14: 133 posts2026-07-15: 243 posts1,609-4%
Price updated 4m ago·X counts updated 2d ago
SLSLS
$SLSSELLAS Life Sciences Group, Inc.
$13.38+13.83%1.6k posts-4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SLS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Binary Phase 3 AML readout is the whole thesis — everything else is size discipline.

Sellas Life Sciences is a small-cap biotech whose entire investment case is the upcoming REGAL Phase 3 readout in acute myeloid leukemia. The stock is up 512% over twelve months on positioning into that binary event.

How to size this without pretending it's not a lottery ticket:

  • The economics are pre-revenue: zero gross margin, zero operating margin, negative free cash flow yield — meaning the entire equity is a claim on the Phase 3 outcome, not on any ongoing operating business.
  • The tape reflects a stampede into the setup: sitting 27% above the 50-day and 141% above the 200-day, at 71% of the 52-week range — that's positioning into the binary that's still coming.
  • The options flow is remarkable: 4.1M call contracts against 6.9M total share volume is the specific tell that market-makers are being forced to source hedging shares, which mechanically amplifies moves in both directions.
  • The retail conviction language is a warning: 'do not set stop losses' and $100+ long-term goals plus 'major medical breakthrough' quotes from the CEO are exactly the setup where a negative readout produces a violent unwind — regulatory language should be measured, and it isn't.

A positive REGAL readout retriggers the acceleration, potentially materially — a negative or ambiguous readout resets this to near-zero given the pre-revenue base. This is a binary bet on one clinical event; size accordingly.

What to watch: The REGAL Phase 3 AML readout timing and result — a positive readout on both efficacy and safety extends the leg materially; an ambiguous or negative readout resets to near-zero given the pre-revenue base. No position size is 'small enough' if you also believe in it.

On the calendar: 2026-08-11 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment44 posts analyzed · as of 2026-07-15

Sellas Life Sciences chatter is euphorically long ahead of the Phase 3 REGAL AML readout. Bulls describe a stock trading $13-15 with call option volume of 4.1M vs total 6.9M share volume - forcing MMs to source shares. Prospero's upside-breakout scan ranks SLS #1. Traders posted repeated 100% Fast Trade wins buying dips under $12.30. PT raises to $25 and $30 have appeared and CEO Angelos Stergiou has publicly used phrases like 'major medical breakthrough' and 'strategic valuations.' Community sets $100+ as long-term goal with 'do not set stop losses' warnings. There is no meaningful bear thread - just some tape-manipulation grievance versus market makers.

Read the AI verdict + X sentiment for $SLS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Developing galinpepimut-S cancer vaccine for acute myeloid leukemia and mesothelioma; late-stage immunotherapy biotech.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SLS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $SLS

Partial — Developing galinpepimut-S cancer vaccine for acute myeloid leukemia and mesothelioma; late-stage immunotherapy biotech; exposure exists but is diluted by diverse end markets and revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-48.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-29.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-47.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 12, 2026$-0.05$-0.06+16.7%
Q4 2025Mar 19, 2026$-0.05$-0.06+21.0%
Q3 2025Nov 12, 2025$-0.06$-0.06+5.3%
Q2 2025Aug 12, 2025$-0.07$-0.08+16.0%
Next earningsTue, Aug 11·consensus EPS $-0.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.05$-8.8M
Q4 FY25$0———$-0.05$-4.9M
Q3 FY25$0———$-0.06$-7.1M
Q2 FY25$0———$-0.07$-7.3M

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$36.1M$36.1M – $36.1M-$0.21-$0.21 – -$0.211
FY27$53.1M$53.1M – $53.1M-$0.13-$0.21 – -$0.041
FY28$122.0M$122.0M – $122.0M$0.01-$0.10 – $0.131
FY29$357.6M$357.6M – $357.6M$1.33$1.33 – $1.331
FY30$630.3M$630.3M – $630.3M$2.55$2.55 – $2.551

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.71%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+26.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+141.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 183.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.425-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 award) in window

See when $SLS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 258-K — Item 5.02: Officer or director change
AI summary

SELLAS Life Sciences updated and standardized executive severance arrangements for three senior officers on June 24, 2026, following a review with an independent compensation consultant. CEO Dr. Angelos Stergiou's employment agreement was amended, while CFO John Burns and Chief Development Officer Dr. Dragan Cicic received amended and restated severance and change-of-control agreements. No specific severance dollar amounts were disclosed in the filing body. Routine compensation governance — no operational or strategic change implied.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-33958 20-8099512 disclosed voting results from its annual or special meeting. rs. Annual Meeting of Stockholders On June 16, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in person or represented by proxy. At the Annual Meeting, the stockholders voted on the following five proposals and cast their vote...

S-3ASRAuto-shelf registrationMar 20S-3ASR
+ 14 other (4 13Gs · 2 routine 8-Ks · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Upseekingalpha.com·3d agoSELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wallbenzinga.com·9d agoSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?benzinga.com·17d agoAmentum Wins NASA'S COSMOS Contract to Advance Spaceflight Mission Operationsgurufocus.com·17d agoSellas Life Sciences: The AML Platform Is More Interesting Than The Binary Eventseekingalpha.com·21d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$ATAI$ALLO
Voices on X · top 11 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport